Skip to content
Government Federal, Medical Health Aged Care

Palliative Care Pharmacist Training gets green light

Pharmaceutical Society of Australia (PSA) 2 mins read

Pharmacists will enhance support for patients receiving palliative care thanks to a new Pharmaceutical Society of Australia (PSA) training program announced as one of the successful recipients of the Australian Government’s National Palliative Care Projects grants program.

The Palliative Care Pharmacist Foundation Training program will upskill pharmacists and improve their capacity to provide palliative care.

PSA also will pilot a community palliative care pharmacist service model, with specialist palliative care pharmacists who have undertaken the training.

The training will be co-designed with subject matter experts, partner organisations and consumers.

PSA National President Dr Fei Sim FPS said the training program came after PSA delivered palliative care education and multiple projects.

“PSA has undertaken a lot of projects leading up to this point, including Primary Health Network projects, such as the Palliative Care Access to Core Medicines (PCAM),” she said.

“In South Australia we’ve delivered numerous projects for palliative care pharmacists in Aboriginal Health, in Aged Care and in community palliative care services.

“These projects have enabled timely access to palliative care medicines and support for end-of-life care for people in residential care and at home.”

Dr Sim said the new training would upskill the most easily accessible health professional to support palliative care in the community.

“Pharmacists already conduct medication reviews in the home and in residential care, providing critical care for patients on multiple medicines,” she said.

“They can provide increased support to patients, carers, including in bereavement with the additional knowledge and skills provided by the training program.”

Funding for the innovative training program and pilot of a new community palliative care pharmacist service model was announced by the Federal Government today as part of $68 million palliative care grants package*.

Dr Sim said people who reported difficulty accessing appropriate palliative care due to gender, cultural, or disability reasons would benefit through pharmacist’s receiving training in delivering care to diverse patient groups.

“Upskilling local pharmacists in palliative care will increase the capacity of community palliative care teams, community pharmacists, and general practitioners to provide care to palliative care patients,” she said.

“The service model pilot will trial and inform an ongoing model of care.

“The pharmacist will increase collaboration and coordination of local palliative care services, reducing unnecessary hospital presentations.”

Training will be available to all Australian registered pharmacists and more information of when it will launch and how to enrol will be communicated in 2024.


About us:

The Pharmaceutical Society of Australia is the only national peak body that represents all of Australia’s pharmacists across all practice settings. We want every Australian to have access to the best healthcare, and this must include optimising access to pharmacists’ knowledge and medicines expertise at the forefront of our healthcare system.


Contact details:

Georgia Clarke   M: 0480 099 798  E: [email protected]

More from this category

  • Government Federal, Taxation
  • 08/12/2025
  • 10:11
Australian Taxation Office

ATO returns over $1 billion in unpaid super to employees

The Australian Taxation Office (ATO) has released new data, revealing $1.1billion in unpaid super has been returned to nearly a million individual’s super funds in 2024–25. Deputy Commissioner Ben Kelly said the latest figures show the ATO’s compliance efforts to protect employee’s super entitlements are continuing to pay dividends. ‘We issued over 200,000proactive reminders and prompts, helping more employers stay on track, as well as taking stronger action against those employers who failed to comply.' The ATO raised almost $800million in Superannuation Guarantee Charge (SGC) liabilities, through: 120,000reminders to employers More than 70,000prompts to employers approximately 15,000audit cases. While most…

  • Medical Health Aged Care
  • 08/12/2025
  • 10:11
BeOne Medicines Ltd.

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 09:40
Miltenyi Biomedicine

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease featuresA 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy.BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.